Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 5/20 | 0.55 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | TTK | P33981 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.51 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 6/20 | 0.50 |
| ▸ | CDK2 | P24941 | 6/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.50 |
| ▸ | CDK4 | P11802 | 3/20 | 0.50 |
| ▸ | CCND1 | P24385 | 3/20 | 0.50 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | CDC7 | O00311 | 2/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclopentanamine SCHEMBL3653733 | 0.94 | IKBKB (0.50) | IKBKBMAPK9MAPK8MAPK10AURKA | |
| SCHEMBL2388344 | 0.88 | MAPK1 (0.59) | IKBKBRETCDK2CCNA2MAPK1 | |
| SCHEMBL1033923 | 0.83 | IKBKB (0.59) | IKBKBMAPK9MAPK8MAPK10AURKA | |
| SCHEMBL3619159 | 0.83 | ADORA1 (0.59) | IKBKBMAPK9MAPK8MAPK10RET | |
| SCHEMBL1030530 | 0.83 | ADORA1 (0.59) | IKBKBMAPK9MAPK8MAPK10RET | |
| SCHEMBL1033674 | 0.82 | CDK1 (0.57) | IKBKBMAPK9MAPK8MAPK10AURKA | |
| SCHEMBL1032138 | 0.82 | IKBKB (0.76) | IKBKBMAPK9MAPK8MAPK10EIF2AK2 | |
| SCHEMBL1034791 | 0.81 | MAPK1 (0.54) | IKBKBMAPK9MAPK8MAPK10CDK1 | |
| SCHEMBL3643870 | 0.80 | MAPK10 (0.58) | IKBKBMAPK9MAPK8MAPK10AURKA | |
| SCHEMBL1034404 | 0.79 | CDK1 (0.51) | IKBKBMAPK9MAPK8MAPK10AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205086-B1 | FUNGICIDAL HETEROCYCLIC AMINES | DU PONT (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20110301123-A1 | Fungicidal Heterocyclic Amines | E.I. DU PONT NEMOURS AND COMPANY (US) | 2011-12-08 | — | — | US | disclosed |
| US-8026359-B2 | Fungicidal heterocyclic amines | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-09-27 | — | — | US | disclosed |
| US-20100267729-A1 | FUNGICIDAL HETEROCYCLIC AMINES | E.I. DU PONT DE NEMOURS AND COMPANY (DE) | 2010-10-21 | — | — | US | disclosed |
| EP-2205086-A2 | FUNGICIDAL HETEROCYCLIC AMINES | E. I. du Pont de Nemours and Company (US) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009061761-A2 | FUNGICIDAL HETEROCYCLIC AMINES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267729-A1 | FUNGICIDAL HETEROCYCLIC AMINES | PRMT9, MAOB, CYP2C9 | IKBKB 3512/4885MAPK9 146/4885MAPK8 3079/4885 |
| US-20110301123-A1 | Fungicidal Heterocyclic Amines | PRMT9, MAOB, CYP2C9 | IKBKB 3512/4885MAPK9 146/4885MAPK8 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.